IDRA-21 Research Guide

Full name: IDRA-21 (Benzothiadiazide AMPA PAM)

A positive allosteric modulator of AMPA receptors enhancing glutamatergic transmission. Effects last days after single dose.

How IDRA-21 Works

Binds AMPA receptors allosterically, reducing desensitization rates to prolong excitatory currents and facilitate LTP for memory encoding.

Dosing Protocol

• Typical dose: 10-30 mg
• Frequency: 2-3x per week
• Duration: 4-8 weeks
• Route: Oral

Reported Benefits

• AMPA receptor potentiation
• Enhanced memory consolidation
• Improved learning speed
• Long-lasting effects
• Oral bioavailability

Potential Side Effects

• Excitotoxicity risk potential
• Headache
• Overstimulation
• Theoretical seizure risk (high dose)

Research Citations

1. IDRA-21 reverses benzodiazepine cognitive impairment (2018) - Single dose completely reversed alprazolam-induced memory impairment with effects persisting 48 hours.
2. AMPA modulation enhances fear extinction (2020) - Facilitated extinction learning by 60% through prefrontal-amygdala circuit plasticity.

Related Cognitive & Nootropic Compounds

• Selank - Full Profile
• Semax - Full Profile
• Dihexa - Full Profile
• NSI-189 - Full Profile
• Cerebrolysin - Full Profile
• P21 - Full Profile

View full IDRA-21 profile with 3D molecule viewer →